Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur J Cancer Care (Engl). 2011 Jul;20(4):549-54. doi: 10.1111/j.1365-2354.2010.01226.x. Epub 2010 Sep 6.

Sleep and daily functioning during androgen deprivation therapy for prostate cancer.

Author information

  • 1Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. hanisch@mail.med.upenn.edu

Abstract

A limited body of evidence suggests that sleep problems are common in prostate cancer patients undergoing androgen deprivation therapy, yet little is known about sleep characteristics and the effects of poor sleep on daily functioning in this population. This study assessed sleep in 60 prostate cancer patients taking androgen deprivation therapy with wrist actigraphy and daily diaries for 7 days. The Epworth Sleepiness Scale and the general version of the Functional Assessment of Cancer Therapy scale were also administered. On average, total sleep time was 5.9 (SD = 1.4) h, and sleep efficiency was 75% (SD = 12.0) as assessed by actigraphy. There was generally poor concordance between actigraphy and daily diary for most sleep metrics. Subjects reported awakening, on average, 2.7 times per night, most commonly for nocturia and hot flashes. Assessment of daily functioning showed that participants had mild daytime sleepiness, which was predicted by total sleep time (F(1,47) = 4.5, P= 0.04) General quality of life was not impaired. This study supports more research on the predictors of poor sleep in order to identify effective interventions.

© 2010 Blackwell Publishing Ltd.

PMID:
20825464
[PubMed - indexed for MEDLINE]
PMCID:
PMC3017240
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing Icon for PubMed Central
    Loading ...
    Write to the Help Desk